KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas

Oral Oncology

Volumn 45, Issue 9, 2009, Pages 826-829

  Dahse, Regine ^a   Driemel, Oliver ^b   Schwarz, Stephan ^c   Kromeyer Hauschild, Katrin ^d   Berndt, Alexander ^d   Kosmehl, Hartwig ^a  

^a HELIOS KLINIKUM ERFURT   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

EGFR targeted therapy; Epidermal growth factor receptor; KRAS; Mutation screening; Salivary gland carcinomas

Indexed keywords

ALANINE; ASPARTIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLYCINE; K RAS PROTEIN; THREONINE;

ACINAR CELL CARCINOMA; ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CODON; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MYOEPITHELIOMA; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; WILD TYPE;

AGED; CARCINOMA; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALIVARY GLAND NEOPLASMS;

EID: 68949205034     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.01.013     Document Type: Article

References (30)

1. Milano A., Longo F., Basile M., Iaffaioli R.V., and Caponigro F. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. Oral Oncol 43 (2007) 729-734
2. Chandana S.R., and Conley B.A. Salivary gland cancers: current treatments, molecular characteristics and new therapies. Expert Rev Anticancer Ther 8 (2008) 645-652
3. Gilbert J., Li Y., Pinto H.A., Jennings T., Kies M.S., Silverman P., et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28 (2006) 197-204
4. Laurie S.A., and Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24 (2006) 2673-2678
5. Rizk S., Robert A., Vandenhooft A., Airoldi M., Kornek G., and Machiels J.P. Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature. Eur Arch Otorhinolaryngol 264 (2007) 587-594
6. Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
7. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008) 1626-1634
8. Barnes L., Eveson W., Reichart P., and Sidransky W. Pathology and genetics of head and neck tumours. World Health Organization classification of tumours (2005), IARC Press, Lyon, France p. 210-42
9. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23 (2005) 5900-5909
10. Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2008; September 17 [Epub ahead of print].
11. Glisson B.S., Blumenschein G., Francisco M., Erasmus J., Zinner R., and Kies M. Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 23 16S (2005) 5532
12. Agulnik M., Cohen E.W., Cohen R.B., Chen E.X., Vokes E.E., Hotte S.J., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25 (2007) 3978-3984
13. Ettl T., Schwarz S., Kuhnel T., Stockmann P., Reichert T.E., and Driemel O. Prognostic value of immunohistochemistry in salivary gland cancer. HNO 56 (2008) 231-238
14. Ettl T., Schwarz S., Kleinsasser N., Hartmann A., Reichert T.E., and Driemel O. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 53 (2008) 567-577
15. Kalyankrishna S., and Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24 (2006) 2666-2672
16. Sheikh Ali M.A., Gunduz M., Nagatsuka H., Gunduz E., Cengiz B., Fukushima K., et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 99 (2008) 1589-1594
17. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
18. Hitt R., Ciruelos E., Amador M.L., Benito A., Sanchez J.J., Ballestin C., et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 41 (2005) 453-460
19. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
20. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18 (2007) 752-760
21. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
22. Parra H.S., Cavina R., Latteri F., Zucali P.A., Campagnoli E., Morenghi E., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91 (2004) 208-212
23. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
24. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26 (2008) 2442-2449
25. Tamura K., Okamoto I., Kashii T., Negoro S., Hirashima T., Kudoh S., et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 98 (2008) 907-914
26. Mitsudomi T., and Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98 (2007) 1817-1824
27. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) e17
28. Schubbert S., Shannon K., and Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7 (2007) 295-308
29. Yamamoto Y., Kishimoto Y., Virmani A.K., Smith A., Vuitch F., Albores-Saavedra J., et al. Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. Hum Pathol 27 (1996) 782-786
30. Yoo J., and Robinson R.A. Ras gene mutations in salivary gland tumors. Arch Pathol Lab Med 124 (2000) 836-839